Table 1.
List of next-generation endocrine agents in development for the management of hormone receptor-positive breast cancer.
| Endocrine agent | Developing company | ET class | Mode of delivery | Disease setting | Phase of development |
|---|---|---|---|---|---|
| Elacestrant (RAD1901) | Radius Health | SERD | Oral | Metastatic; neoadjuvant | 3 complete |
| Amcenestrant (SAR439859) | Sanofi | SERD | Oral | Metastatic; adjuvant | 2–3 |
| Camizestrant (AZD9833) | Astra Zeneca | SERD | Oral | Metastatic; neoadjuvant | 2–3 |
| Giredestrant (GDC-9545) | Genentech/Roche | SERD | Oral | Metastatic; adjuvant; neoadjuvant | 2–3 |
| Imlunestrant (LY3484356) | Eli Lilly | SERD | Oral | Metastatic; neoadjuvant | 1 |
| Rintodestrant (G1T48) | G1 Therapeutics | SERD | Oral | Metastatic | 1–2 |
| Borestrant (ZB-716) | Zeno Pharma | SERD | Oral | Metastatic | 1 – 2 |
| ZN-c5 | Zentalis | SERD | Oral | Metastatic | 1–2 |
| D-0502 | Inventisbio | SERD | Oral | Metastatic | 1 |
| Lasofoxifene | Sermonix | SERM | Oral | Metastatic | 2 |
| Bazedoxifene | Pfizer | SERM/SERD Hybrid | Oral | Metastatic; DCIS | 2 |
| H3B-6545 | H3 Biomedicine | SERCA | Oral | Metastatic | 1–2 |
| OP-1250 | Olema Oncology | CERAN | Oral | Metastatic | 1–2 |
| ARV-471 | Arvinas | PROTAC | Oral | Metastatic | 1–2 |
| AC682 | Accutar Biotech | Chimeric ER Degrader | Oral | Metastatic | 1 |
AI, aromatase inhibitors; CERAN, complete estrogen receptor antagonist; ET, endocrine therapy; PROTAC, proteolysis targeting chimer; SERCA, selective estrogen receptor covalent antagonist; SERD, selective estrogen receptor degrader; SERM, selective estrogen receptor modulator.